Randomized Trial of HYBRID Coronary Revascularization Versus Percutaneous Coronary Intervention

March 30, 2018

  • Clinical Trial Information

    Trial Contact: Peisner, Pamela

    Trial Phone: 321.843.1037

  • IRB No: 17.010.02

    Protocol Abbrev: HYBRID

    Principal Investigator: Steven J. Hoff, MD

    Sub Investigators: Ball, Stephen; Garcia Fernandez, Joel A MD; Gupta, Ashish MD; Kasi, Vijaykumar MD; Steiner, Mark MD; Vivek, Deepak MD; Abbott, Lionel Charme MD

    Phase: Device: Significant Risk

    Age Group: Adult

    Treatment: Surgery vs Interventional Procedure

    Applicable Disease Sites: Coronary Artery Disease

    Therapies Involved: Surgery

  • Objective

    To evaluate the effectiveness and safety of hybrid coronary revascularization (HCR) compared to multi–vessel percutaneous cardiac intervention (PCI) with metallic drug-eluting stents (DES) in patients with multi-vessel coronary artery disease (CAD) involving the Left Anterior Descending (LAD) and/or Left Main (LM) arteries. The primary objective of this trial is to determine whether hybrid coronary revascularization is associated with a reduction in Major Adverse Coronary and Cerebrovascular Events (MACCE) compared to PCI with DES.

  • Key Eligibility

    Coronary Artery Disease
    Open Heart Surgery